Among community-dwelling U.S. adults living with cancer and/or ASCVD, co-existing disease was associated with substantially higher mortality and underscore the importance of integrated cardio-oncology care.
Abstract
Background Despite increasing evidence on the bi-directional association between cancer and atherosclerotic cardiovascular disease (ASCVD), less is known about differences in mortality among individuals with co-existing diseases. Objective We examined all-cause and disease-specific mortality among U.S. adults living with cancer, ASCVD, and co-existing cancer and ASCVD. Methods Among adults aged ≥18 years in the National Health Interview Survey (2005-2018) linked to the National Death Index (through December 31, 2019), we estimated multivariable-adjusted HRs (aHRs) and 95% CIs using Cox proportional hazards models. Mortality outcomes were compared across individuals with cancer alone, ASCVD alone, and co-existing conditions, relative to those with neither condition. Results Among 388,632 individuals, 1.3% had co-existing cancer and ASCVD, representing approximately 3.0 million U.S. adults annually. Over a mean follow-up of 7.2 years, co-existing disease was associated with the highest all-cause mortality (aHR, 2.45 [95% CI: 2.23-2.70]), exceeding ASCVD alone (aHR, 1.93 [1.82-2.04]) and cancer alone (aHR, 1.90 [1.77-2.04]). Co-existing disease was associated with elevated risks of both cancer mortality (aHR, 4.18 [3.48-5.03]) and cardiovascular mortality (aHR, 2.73 [2.30-3.24]). Among those living with co-existing diseases, older age (≥75 years) (aHR, 6.02 [1.97-18.37]), diabetes (aHR, 1.23 [1.03-1.46]), and current/former smoking status (aHR, 1.26 [1.07-1.49]) were associated with increased hazards of all-cause mortality. Conclusions Among community-dwelling U.S. adults living with cancer and/or ASCVD, co-existing disease was associated with substantially higher mortality. These findings highlight the elevated burden of mortality among individuals with co-existing cancer and ASCVD and underscore the importance of integrated cardio-oncology care.
Cancer remains a leading cause of mortality globally, while hypertension is the primary contributor to cardiovascular disease and premature death. These conditions frequently coexist; hypertension may precede cancer due to shared risk factors or arise during or after cancer treatment, partly as a result of the hyperten...
Bahaa Mali, Ali Mali, Alaa Mali et al.· Scientific Reports· 0 citations
The overall AAMR declined substantially over the 25-year study period, with the most pronounced reductions occurring in the mid-2000s, followed by a marked deceleration after 2019, which highlighted the need for targeted equitable access to guideline-directed vascular care.
Pre-existing CVD at cancer diagnosis has increased substantially over 2 decades and is projected to affect nearly half of patients by 2050, which underscores the need for the expansion of cardio-oncology services.
A. Alshahrani, E. Kontopantelis, C. Morgan et al.· European Heart Journal· 0 citations
Background: Type 2 diabetes (T2D) is associated with elevated rates of several cancers and is increasingly recognized as a heterogeneous disease, but whether its clinically distinct subtypes carry different cancer risks is unknown. Methods: In this matched retrospective cohort study using electronic health record data...
Z. Li, C. Liu, M. B. Weber et al.· medRxiv· 0 citations
Breast cancer mortality among older U.S. adults declined significantly between 1999 and 2020, but the increasing absolute number of deaths and persistent age, racial, ethnic, and geographic disparities indicate a continuing public health burden.
Tong Feng, Peng-Cheng Zheng, Qing-Yuan Li et al.· Frontiers in Oncology· 0 citations
Despite declining overall CRC mortality, recent increases were observed in several metastatic and noncancer contributing conditions, and model-based projections indicate that overall lung metastasis mortality will continue to increase through 2040, whereas liver metastasis mortality will peak in 2028 and subsequently d...
Zi-Chen He, Ya-Dong Chen, Yu-Xing Hu et al.· Frontiers in Public Health· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.